Atria Wealth Solutions Inc. decreased its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 14.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 42,744 shares of the company's stock after selling 7,291 shares during the quarter. Atria Wealth Solutions Inc.'s holdings in AstraZeneca were worth $3,142,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in AZN. Brighton Jones LLC grew its position in AstraZeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock worth $379,000 after buying an additional 2,789 shares during the last quarter. American Assets Inc. acquired a new position in AstraZeneca in the fourth quarter worth approximately $426,000. Norges Bank acquired a new position in AstraZeneca in the fourth quarter worth approximately $1,073,000. Geode Capital Management LLC grew its position in AstraZeneca by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 498,831 shares of the company's stock worth $32,683,000 after buying an additional 5,384 shares during the last quarter. Finally, Cerity Partners LLC grew its position in AstraZeneca by 4.2% in the fourth quarter. Cerity Partners LLC now owns 207,860 shares of the company's stock worth $14,871,000 after buying an additional 8,435 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.
AstraZeneca Price Performance
Shares of AZN opened at $74.57 on Friday. The business's 50-day moving average is $71.84 and its 200-day moving average is $71.59. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The company has a market capitalization of $231.27 billion, a price-to-earnings ratio of 28.03, a P/E/G ratio of 1.36 and a beta of 0.36. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. During the same quarter in the prior year, the business earned $1.24 EPS. The company's revenue for the quarter was up 16.1% compared to the same quarter last year. Equities research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.
AstraZeneca Cuts Dividend
The company also recently disclosed a semi-annual dividend, which will be paid on Monday, September 8th. Investors of record on Friday, August 8th will be issued a dividend of $0.505 per share. This represents a dividend yield of 200.0%. The ex-dividend date is Friday, August 8th. AstraZeneca's dividend payout ratio (DPR) is currently 77.44%.
Analyst Ratings Changes
AZN has been the topic of several recent research reports. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research report on Wednesday, July 9th. BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, AstraZeneca presently has an average rating of "Moderate Buy" and a consensus price target of $89.00.
Check Out Our Latest Analysis on AZN
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
